Tamoxifen - The treatment of choice. Why look for alternatives?

British Journal of Cancer

Volumn 78, Issue SUPPL. 4, 1998, Pages 1-4

  Baum, M ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Charles Bell House   (United Kingdom)

Author keywords

Adjuvant; Aromatase inhibitors; Breast cancer; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; GOSERELIN; TAMOXIFEN;

ADVANCED CANCER; ARTICLE; BONE ATROPHY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG POTENTIATION; EARLY CANCER; ENDOMETRIUM CANCER; EYE TOXICITY; HUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; ENDOMETRIAL NEOPLASMS; FEMALE; GUIDELINES; HUMANS; MIDDLE AGED; RECEPTORS, ESTROGEN; SURVIVAL RATE; TAMOXIFEN;

EID: 0031717236     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.753     Document Type: Article

References (35)

1. Anonymous (1997) New aromatase inhibitors for breast cancer. Drug Ther Bull 35: 55-56
2. Assikis VJ, Neven P, Jordan VC and Vergote I (1996) A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 32A: 1464-1476
3. Bahamonde J, Bazzani M, Bernasconi C, et al (1997) Tamoxifen therapy for cyclical mastalgia: dose randomized trial. Breast 6: 212-213
4. Baum M (1997) Tamoxifen. Endocr Rel Cancer 4: 237-243
5. Bilimoria MM, Jordan VC and Morrow M (1996) Additional benefits of tamoxifen for postmenopausal patients. In Tamoxifen - a Guide for Clinicians and Patients. Jordan VC (ed.), 75-87. PRR: Huntingdon
6. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV (On behalf of the 'Arimidex' Study Group) (1996) Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 14: 2000-2011
7. Buzdar A, Jonat W, Howell A, Yin H and Lee D (1997) Significantly improved survival with 'Arimidex' (anastrozole) versus megestrol acetate in postmenopausal advanced breast cancer: updated results of two randomized trials (abstract 156). Proc Am Soc Clin Oncol 16: 545
8. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group (1996) Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in women aged 50 years or older with breast cancer. J Natl Cancer Inst 88: 1834-1839
9. DeFriend DJ and Howell A (1994) Tamoxifen withdrawal responses: chance observations or clinical clues to antioestrogen resistance. Breast 3: 199-201
10. Dewar JA, Horobin JM, Preece PE, Tavendale R, Tunstall-Pedoe H and Wood RAB (1992) Long-term effects of tamoxifen on blood lipid levels in breast cancer. Br Med J 305: 225-226
11. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-15, 71-85
12. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (9114): 1451-1467
13. Fentiman IS, Caleffi M, Hamed H, Chaudary MA (1988) Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial. Br J Surg 75: 845-846
14. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL and Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 [prior annotation incorrect]. J Natl Cancer Inst 86: 527-537
15. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschênes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J and Lickley HL (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88: 1529-1542
16. Fisher B, Dignam J, DeCillis DL, et al (1997) The worth of chemotherapy and tamoxifen (TAM) over TAM alone in node-negative patients with estrogen-receptor positive invasive breast cancer: first results from NSABP B-20 (abstract). Proc Am Soc Clin Oncol 16, 1a
17. Forbes JF (1997) The control of breast cancer: the role of tamoxifen. Semin Oncol 24 (suppl. 1): (S1) 5-19
18. Jaiyesimi IA, Buzdar AU, Decker DA and Hortobagyi GN (1995) Use of tamoxifen for breast cancer: twenty-eight years later [see comments]. J Clin Oncol 13: 513-529
19. Jonat W, Kaufmann M, Blamey RW, Howell A, Collins JP, Coates A, Eiermann W, J'anicke F, Njordenskold B and Forbes JF (1995) A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer 31A: 137-142
20. Katzenellenbogen BS, Montano MM, Ekena K, Herman ME and McInerney EM (1997) William L. Maguire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat 44: 23-38
21. Koss LG, Schreiber K, Oberlander SG, Moussouris HF and Lesser M (1984) Detection of endometrial carcinoma and hyperplasia in asymptomatic women. Obstet Gynecol 64: 1-11
22. Love RR, Mazess RB, Barden HS, et al (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852-856
23. Love RR, Wiebe DA, Feyzi JM, Newcomb PA and Chappell RJ (1994a) Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 86: 1534-1539
24. Love RR, Wiebe DA, Feyzi JM, et al (1994b) Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 86: 1534-1539
25. MacMahon B ( 1997) Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist. Semin Oncol 24 (suppl. 1): (S1) 122-139
26. Muss HB (1992) Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat 21: 15-26
27. Nayfield SG and Gorin MB (1996) Tamoxifen-associated eye disease: a review. J Clin Oncol 14: 1018-1026
28. Nolvadex Adjuvant Trial Organisation (1983) Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Lancet i: 257-261
29. Peto R (1996) Five years of tamoxifen - or more? J Natl Cancer Inst 88: 1791-1793
30. Powles TJ (1997) Efficacy of tamoxifen as treatment of breast cancer. Semin Oncol 24(suppl. 1):S48-54
31. Powles TJ, Hickish T, Kanis JA, Tidy A and Ashley S (1996) Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14: 78-84
32. Quinn M and Allen E (1995) Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. Br Med J 311: 1391-1395
33. Rose C and Mouridsen HT (1988) Endocrine therapy of advanced breast cancer. Acta Oncol 27: 721-728
34. Swedish Breast Cancer Cooperative Group (1996) Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88: 1543-1549
35. Tormey DC, Gray R and Falkson HC (1996) Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst 88: 1828-1833